The candidate will be in charge of developing clonal patient-derived organoid (PDO) models from resections. Based on the know-how of the Biomics and LSMB teams, 3D cell cultures will be produced by clonal development within extracellular matrix microbeads reproducing the physiological microenvironment of the cells. The microbeads are produced semi-automatically in a dedicated instrument. Your mission will be to develop the protocol for extracting and selecting tumor cells from heterogeneous tumor samples, and to produce the corresponding clonal PDOs in extracellular matrix microbeads. The clonal subpopulations will then be isolated, amplified and characterized on the basis of their genotypes and phenotypes to study the variability of responses of different clonal subpopulations to exposure to pharmaceutical compounds. Your contribution to the team's progress will focus on building up a biobank of characterized PDO models and performing and qualifying compound assays on single and multipatient tumor models. Bibliography: M. E. Dolega et al., Biomaterials, 2015, 52, 347-357. B. Laperrousaz et al., Nucl. Acids Res., 2018, 46, e70. S. Porte et al., Proc. European Organ-On-Chips Society (EUROoCS), p. 342, Milano, Italy, 2024. Required work: - Extraction and selection of tumor cells from patient samples. - Production of clonal tumoroids encapsulated in extracellular matrix microbeads. - Sorting, isolation and amplification of clonal subpopulations. - Characterization of mutations and phenotypes in each clonal subpopulation. - Preservation of patient tumor clones in a biobank. - Development of standardized patient tumor models. - Toxicological testing of therapeutic compounds and biotherapies on tumor models.